Randomized phase 2 study of tivantinib plus erlotinib vs single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer
Lung Cancer Jan 22, 2018
Gerber DE, et al. - The current study was conducted to evaluate tivantinib plus erlotinib vs single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer (NSCLC). Findings did not support the superiority of the combination of the MET inhibitor tivantinib and erlotinib to conventional single-agent chemotherapy in these patients.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
